Loading...

UK Government And NHS Spending Will Unlock Enduring Opportunities

Published
17 Feb 25
Updated
05 Sep 25
AnalystConsensusTarget's Fair Value
₹3,093.33
20.3% undervalued intrinsic discount
05 Sep
₹2,464.40
Loading
1Y
-6.8%
7D
-1.7%

Author's Valuation

₹3.1k

20.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on05 Sep 25

With both the discount rate and future P/E for Mastek remaining essentially unchanged, the consensus analyst price target was maintained at ₹3093. What's in the News Upcoming board meeting to review June 2025 quarterly financial results and consider re-appointment of Suresh Vaswani as Independent Director for a second term.

Shared on01 May 25
Fair value Increased 6.77%

Shared on23 Apr 25
Fair value Decreased 11%

AnalystConsensusTarget has decreased revenue growth from 13.9% to 12.1%.

Shared on17 Apr 25
Fair value Decreased 0.58%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 4.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 3.57%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 3.41%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 3.33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Increased 7.73%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.